Higher baseline levels of OPN (Pintx=0.0167), VCAM-1 (Pintx=0.0216), and PDGF-AA (Pintx=0.0435) appeared to predict for PFS benefit from regorafenib compared to placebo. VCAM-1 was also potentially predictive of OS benefit from regorafenib compared to placebo (Pintx=0.0124)....The key findings of this study suggest that VCAM-1 may be a predictive biomarker for regorafenib benefit while multiple protein markers may be prognostic of outcome in mCRC patients.